Ginsenosides Rg1, Rb1 and rare ginsenosides: Promising candidate agents for Parkinson's disease and Alzheimer's disease and network pharmacology analysis
Authors:
Top Cited Papers
Open Access
- 5 January 2025
- journal article
- research article
- Published by Elsevier in Pharmacological Research
- Vol. 212, 107578
Abstract
No abstract availableKeywords
This publication has 125 references indexed in Scilit:
- Neuroprotection and mechanisms of ginsenosides in nervous system diseases: Progress and perspectivesIUBMB Life, 2024
- Amelioration of Amyloid‐β Induced Alzheimer's Disease by Bacopa monnieri through Modulation of Mitochondrial Dysfunction and GSK‐3β/Wnt/β‐Catenin SignalingMolecular Nutrition & Food Research, 2023
- Empagliflozin repurposing in Parkinson’s disease; modulation of oxidative stress, neuroinflammation, AMPK/SIRT-1/PGC-1α, and wnt/β-catenin pathwaysInflammopharmacology, 2023
- Autophagy and apoptosis cascade: which is more prominent in neuronal death?Cellular and Molecular Life Sciences, 2021
- NGF and the Amyloid Precursor Protein in Alzheimer’s Disease: From Molecular Players to Neuronal Circuits2021
- Protective effect of ginsenoside Rh2 on scopolamine‐induced memory deficits through regulation of cholinergic transmission, oxidative stress and the ERK‐CREB‐BDNF signaling pathwayPhytotherapy Research, 2020
- Gensenoside Rb1 protects rat PC12 cells from oxidative stress-induced endoplasmic reticulum stress: the involvement of thioredoxin-1Molecular and Cellular Biochemistry, 2015
- Rg1 protects iron‐induced neurotoxicity through antioxidant and iron regulatory proteins in 6‐OHDA‐treated MES23.5 cellsJournal of Cellular Biochemistry, 2010
- Ginsenoside Rd attenuates neuroinflammation of dopaminergic cells in culture2007
- Ginsenosides Rb1 and Rg1 effects on survival and neurite growth of MPP + -affected mesencephalic dopaminergic cellsJournal of Neural Transmission, 2004